ReviewFrontiers in microbiology2019
Mother-to-Child HTLV-1 Transmission: Unmet Research Needs.
Review in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 3 syntheses or guidelines pooled it, 127 citations in OpenAlex.
- The Global Prevalence of HTLV-1 and HTLV-2 Infections among Immigrants and Refugees-A Systematic Review and Meta-Analysis.Viruses · 2024Pooled it
- Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies.BMC infectious diseases · 2023Pooled it
- Pooled it
- Emerging Risk for Human T-Cell Leukemia Virus Type 1 Transmission with HIV-Positive Breastfeeding Support.Emerging infectious diseases · 2026Review
- Distribution of adult T-cell leukaemia/lymphoma subtypes and survival outcomes across geographical regions: An international retrospective cohort study.British journal of haematology · 2026Article
- Prevalence of Human T-Lymphotropic Viruses 1 and 2 in Individuals Infected with Hepatitis C Virus in Belém do Pará, Brazil.Tropical medicine and infectious disease · 2026Article
- Observational
- HTLV-1 and HTLV-2 Seroprevalence among Milk Donors in Shiraz, Southern Iran: A Letter to the Editor.Iranian journal of medical sciences · 2026Article
- Construction and validation of a notification instrument for cases of human T-cell lymphotropic virus infection: methodological study, Natal, 2025.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2026Article
- Adult T-cell leukemia/lymphoma: molecular pathogenesis, emerging therapies, and future directions.Frontiers in oncology · 2026Review
- HTLV-1 and ATLL: Epidemiology, Oncogenesis, and Opportunities for Community-Informed Research in the United States.Viruses · 2025Review
- A comprehensive assessment using multiple factors based on HAS-Flow analysis predicts ATL development and progression.Scientific reports · 2025Article
- Development and optimization of human T-cell leukemia virus-specific antibody-dependent cell-mediated cytotoxicity (ADCC) assay directed to the envelope protein.Journal of virology · 2025Article
- HTLV-1 and Pregnancy: A Retrospective Study of Maternal and Neonatal Health Outcomes in an Endemic Region of Brazil.Pathogens (Basel, Switzerland) · 2025Observational
- Stability and Perpetuation of Human T-Lymphotropic Virus 1 (HTLV-1) in Intrafamilial Transmissions of Infection in an Endemic Region of the Brazilian Amazon: A Pilot Study.Journal of tropical medicine · 2025Article
- Silent dissemination of HTLV-1: evidence of intrafamilial transmission in a Brazilian reference centre.Memorias do Instituto Oswaldo Cruz · 2025Article
- Article
- The Assembly of HTLV-1-How Does It Differ from HIV-1?Viruses · 2024Review
- Article
- Urgent need to prevent mother-to-child transmission of HTLV-1 in Jamaica.Lancet regional health. Americas · 2024Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mother-to-child transmission (MTCT) of Human T-cell lymphotropic virus type 1 (HTLV-1) causes lifelong infection. At least 5-10 million individuals worldwide are currently living with HTLV-1. Studies of regional variation are required to better understand the contribution of MTCT to the global burden of infection. Although most infected individuals remain asymptomatic ∼10% develop high morbidity, high mortality disease. Infection early in life is associated with a higher risk of disease development. Adult T-cell leukemia (ATL), which is caused by HTLV-1 and has a median survival of 8 months is linked to MTCT, indeed evidence of ATL following infection as an adult is sparse. Infective dermatitis also only occurs following neonatal infection. Whilst HTLV-1-associated myelopathy (HAM) follows sexual and iatrogenic infection approximately 30% of patients presenting with HAM/TSP acquired the infection through their mothers. HAM/TSP is a disabling neurodegenerative disease that greatly impact patient's quality of life. To date there is no cure for HTLV-1 infection other than bone marrow transplantation for ATL nor any measure to prevent HTLV-1 associated diseases in an infected individual. In this context, prevention of MTCT is expected to contribute disproportionately to reducing both the incidence of HTLV-1 and the burden of HTLV-1 associated diseases. In order to successfully avoid HTLV-1 MTCT, it is important to understand all the variables involved in this route of infection. Questions remain regarding frequency and risk factors for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.